On Tuesday, Shares of Southwest Airlines Co (NYSE:LUV), gained 1.51% to $38.36.
Southwest Airlines Co., stated its July and year-to-date preliminary traffic statistics. The Company flew 11.5 billion revenue passenger miles (RPMs) in July 2015, an 8.2 percent enhance from the 10.6 billion RPMs flown in July 2014. Accessible seat miles (ASMs) raised 7.0 percent to 13.1 billion in July 2015, contrast with the July 2014 level of 12.3 billion. The July 2015 load factor was an all-time record 87.7 percent, contrast with 86.7 percent in July 2014. Based on these results and current trends, the Company estimates its third quarter 2015 operating revenue per ASM (RASM) will decrease about 1.0 percent, contrast with third quarter 2014.
For the first seven months of 2015, the Company flew 68.2 billion RPMs, contrast with 63.4 billion RPMs flown for the same period in 2014, an enhance of 7.6 percent. Year-to-date ASMs raised 6.6 percent to a level of 81.9 billion, contrast with the 76.8 billion for the same period in 2014. The year-to-date load factor was 83.3 percent, contrast with 82.5 percent for the same period in 2014.
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Shares of OvaScience Inc (NASDAQ:OVAS), declined -3.73% to $25.07, during its last trading session.
OvaScience, declared that a peer-reviewed journal will publish analyses of the AUGMENTSM treatment that show statistically noteworthy higher ongoing clinical pregnancy rates contrast to standard in vitro fertilization (IVF). This will be the first publication of physician experience using the AUGMENT treatment and comprises a new analysis by Fakih IVF in the United Arab Emirates (UAE) in which eggs from the same woman during the same IVF cycle were prospectively allocated to two treatment groups: one group of eggs received the AUGMENT treatment during IVF and the other group of eggs received only IVF. Higher rates of embryo transfer occurred with the AUGMENT treatment based on standard embryo quality measures.
Physician experiences from Michael Fakih, M.D., Co-Founder and Medical Director of Fakih IVF, and Robert F. Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners in Canada, are predictable to appear in the August 25, 2015, peer-reviewed, Journal of Fertilization: In Vitro– IVF-Worldwide Reproductive Medicine, Genetic & Stem Cell Biology. The publication also comprises a summary of over 90 patients treated at Fakih IVF and TCART, many of whom were the subject of previous presentations at recent fertility meetings. Drs. Fakih and Casper have used the AUGMENT treatment in clinical practice since 2014, each focusing initially on poor prognostic women with histories of failed IVF cycles. The AUGMENT treatment is not accessible in the United States.
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman’s own ovaries.
Finally, Allison Transmission Holdings Inc (NYSE:ALSN), ended its last trade with -1.64% loss, and closed at $29.42.
Allison Transmission Holdings Inc. and the Ann Arbor Area Transportation Authority, have dedicated the first of 60 new buses equipped with the latest advances in fuel economy technology. Referred to as xFE, designating extra fuel economy, the new fully automatic bus transmission has demonstrated improvements up to 7 percent.
“This dedication ushers in a new era for fuel economy technology,” said Heidi Schutte, executive director of North America sales for Allison Transmission. “As a customer for more than 20 years, we’re happy TheRide is the first transit agency in the world to feature our new xFE automatic transmission.”
Allison Transmission Holdings, Inc., together with its auxiliaries, designs, manufactures, and sells commercial and defense fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium- and heavy-tactical U.S. defense vehicles.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
